E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 3.09 SEK 3% Market Closed
Market Cap: 750.1m SEK

Operating Margin
Enzymatica AB (publ)

-106.6%
Current
-113%
Average
6.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-106.6%
=
Operating Profit
-51.6m
/
Revenue
48.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Enzymatica AB (publ)
STO:ENZY
750.1m SEK
-107%
US
Eli Lilly and Co
NYSE:LLY
689.1B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
369.2B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
48%
CH
Roche Holding AG
SIX:ROG
209B CHF
33%
CH
Novartis AG
SIX:NOVN
183.2B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP
24%
US
Merck & Co Inc
NYSE:MRK
193.7B USD
34%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
FR
Sanofi SA
PAR:SAN
117.5B EUR
22%

Enzymatica AB (publ)
Glance View

Market Cap
750.1m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
2.04 SEK
Overvaluation 34%
Intrinsic Value
Price
E
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-106.6%
=
Operating Profit
-51.6m
/
Revenue
48.4m
What is the Operating Margin of Enzymatica AB (publ)?

Based on Enzymatica AB (publ)'s most recent financial statements, the company has Operating Margin of -106.6%.

Back to Top